Cancer, colorectal and others: Aspirin for primary or secondary prevention
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2018 10 18;379(16):1519-1528 Randomized Controlled Trial, Multicenter Study
IN atherosclerosis, cardiovascular disease, primary prevention, healthy old patients The Use of
aspirin, 100 mg daily
As Prevention, Primary
Is worse Than
placebo
To carry any benefit: it increased all-cause death (1.3 %/year aspirin VS 1.1%/year placebo, p significant), mainly caused by cancer.
Lancet. 2011 Jan 1;377(9759):31-41. Epub 2010 Dec 6 Meta-Analysis
IN cancer, all types, gastrointestinal cancers The Use of
aspirin, 75 mg daily or more, for more than 5 years
As Prevention, Primary
Is better Than
placebo
To reduce death due to all cancers (0.79) when treatment maintained for more than 5 years, specially for gastrointestinal cancers (OR 0.46) but also for brain, lung and prostate cancers.
Lancet. 2010 Nov 20;376(9754):1741-50 Meta-Analysis
IN cancer, colorectal The Use of
aspirin dose, 75 mg daily or more, for more than 5 years
As Prevention, Primary
Is better Than
placebo
To reduce the 20-year risk of colon cancer incidence (HR 0.76) and mortality (HR 0.65), specially of proximal colon cancer.
N Engl J Med. 2003 Mar 6;348(10):883-90 Randomized Controlled Trial, Multicenter Study
IN cancer, colorectal The Use of
aspirin (325 mg daily)
As Prevention, Secondary
Is better Than
placebo
To prevent new colorectal adenomes in colonoscopy, at 12,8 months (17% in intv VS 27% in ctrl)